NCT00165659已完成2 期
A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 65
- 主要终点
- Primary Outcomes: Efficacy:
研究概览
简要总结
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures. Safety of E2020 will also be evaluated.
(*for overall evalution of clinical symtoms) (**for cognitive function test)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnostics of Alzheimer's disease (AD) according to DSM-IV.
- •Patients with modified Hachinski Ischemic scale score of ≦
- •FAST score of ≧6 at baseline (4 weeks before starting study treatment).
- •MMSE score between 1 and 12 at baseline (4 weeks before starting study treatment).
- •Imaging diagnostics (CT, MRI, etc., within 24 months consistent with the diagnosis of AD without any other comorbid pathologies found. If a significant change in clinical status suggesting other types of dementia (except AD) is suspected between the final image diagnosis and the time of starting observation, the scan test should be repeated.
- •Patients who can comply with the requirements on concomitant drugs/therapies from the baseline phase or before.
- •Patients aged 50 years or older.
- •Outpatients. Even in the case of an outpatient or a patient attending on the outpatient-visit basis from a nursing home facility, the caregiver must be a constant and reliable informant with minimum of 3 days per week direct contact with the patient (for at least 4 hours per day on waking hours). This contact is necessary to ensure accurate reporting of the patient's behavior and his/her ability to perform ADLs.
- •Patients who are expected to complete all procedures scheduled during the Screening and Baseline visit and who have a reliable caregiver or family member who agrees to accompany the patient to all clinic visits, provide information about the patient as required by the protocol, and ensure compliance with the treatment schedule.
- •Patients who can swallow tablets without pulverization.
- •Patients who are ambulatory at least aided (walker) and have vision and hearing necessary for compliance with testing procedures (eyeglasses and/or hearing aid permissible).
- •Patients whose representatives can sign the written informed consent.
排除标准
- •Patients with dementia other than AD.
- •Patient whose imaging test shows "circumscribed cerebral lesion or multiple infarcts" which is suspected to be the responsible cause of dementia (mixed-type dementia)
- •Patients with other types of dementia
- •Patients with a current DSM-IV diagnosis of major depressive disorder or any current serious psychiatric diagnosis othe than AD.
- •Patients without a reliable caregiver.
- •Patients who are expected to enter a nursing home facility within 6 months after starting study treatment (excluding a transient entry).
- •Patients with active or clinically significant conditions affecting absorption, distribution or metabolism of study drugs (e.g., inflammatory bowel disease, gastric or duodenal ulcers, or severe lactose intolerance).
- •Patients with a known hypersensitivity to a component of donepezil hydrochloride preparation or piperidine derivatives.
- •Patients complicated with a severe gastrointestinal, hepatic, renal, endocrine, or cardiovascular system disease (e.g., sick sinus syndrome, intraarterial and supraventricular conduction disorder, etc.).
- •Patients with a history of severe bronchial asthma or obstructive pulmonary disease.
- •Patients with a severe extrapyramidal disease (Parkinson's disease, Parkinson's syndrome, etc.).
- •Patients with diabetes mellitus with uncontrolled blood glucose levels (HbAlc of ≧10%).
- •Hypertension patients with uncontrolled blood pressure (diastolic blood pressure of ≧95 mmHg).
- •Patients with uncontrolled thyroid dysfunction.
- •Patients with a history of seizure or convulsion within the previous 3 months (obtaining informed consent).
- •Patients with a known or suspected history of alcohoism or drug dependence within the recent 10 years.
- •Patients with malignant tumors.
- •Women of pregnant, possibly pregnant, or lactating.
- •Patients who have participated in another clinical study within the recent 3 months (before giving consent).
- •Any other patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
结局指标
主要结局
Primary Outcomes: Efficacy:
CIBIC plus*, SIB**
(*for overall evalution of clinical symtoms)
(**for cognitive function test)
Safety:
Adverse event, adverse drug reaction, vital sign, clinical laboratory parameter, electrocardiogram
次要结局
- Efficacy
- Behave-AD, ADCS-ADL-sev
研究者
研究点 (65)
Loading locations...
相似试验
已完成
2 期
Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe ConjunctivochalasisConjunctivochalasisNCT02804191Ocuwize LTD62
已完成
3 期
A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux DiseaseNon-erosive Gastroesophageal Reflux DiseaseNCT00165646Eisai Co., Ltd.288
已完成
2 期
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic GastroparesisDiabetes Mellitus, Type 1GastroparesisDiabetes Mellitus, Type 2NCT01452815Tranzyme, Inc.201
已完成
3 期
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With LevodopaParkinson's DiseaseNCT00203060Teva Neuroscience, Inc.404
已完成
2 期
An Efficacy and Safety Study of CNTO 148 Subcutaneous Injection Compared With Placebo in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00207714Centocor, Inc.172